Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT00408447
PHASE2

Stem Cell Transplant in Sickle Cell Disease and Thalassemia

Sponsor: Columbia University

View on ClinicalTrials.gov

Summary

The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately ablative) will result in successful bone marrow replacement without as severe side-effects but with permanent control of the disease. Patients will receive a chemotherapy regimen with busulfan, fludarabine, and alemtuzumab followed by an infusion of stem cells, either from a family-related or cord-blood matched donor.

Official title: Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and Thalassemia

Key Details

Gender

All

Age Range

1 Month - 30 Years

Study Type

INTERVENTIONAL

Enrollment

53

Start Date

2004-09

Completion Date

2025-02

Last Updated

2024-06-13

Healthy Volunteers

No

Interventions

DRUG

Busulfan

Busulfan 4 mg/kg/d x 4d

DRUG

Fludarabine

Fludarabine 30 mg/m2/d x 6d

DRUG

Alemtuzumab

Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d

PROCEDURE

Allogeneic stem cell transplant

Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.

Locations (1)

Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University

New York, New York, United States